Zesban Muhammedi
Managing Partner at MBX Capital
Washington, District of Columbia
Overview
Work Experience
Co-founder & Managing Partner
2020 - Current
Venture capital for environmental health and healthcare infrastructure startups tackling the root causes of why we get sick. Learn more at mbxcapital.com
MBX Capital is a venture capital partnership investing in early-stage healthcare, life sciences, and environmental health companies
Member, Board of Directors
2023
Macro Trials is the precision research clinical platform, driving increased research velocity and an amplified patient experience to unlock value for all stakeholders in the clinical trial ecosystem. Via its digitally powered infrastructure and "hub-and-spoke" distributed model, Macro partners with pharmaceutical companies, CROs, providers, and health systems to conduct trials for high-value therapeutics. The company’s turnkey platform empowers physicians to participate in groundbreaking research via workflow-native efficiency tools, clinical research personnel and a network of logistic partners. Macro’s clinical trial intelligence platform and proprietary real-world evidence as a service (RWEaaS) product supports life sciences companies in all aspects of therapeutic research, development, and commercialization.
Clinical trials. Reimagined.
Raised $6,000,000.00 from MBX Capital, Initiate Ventures, Healthy Ventures, Village Global and Inflect Health.
Kauffman Fellow | Class 25
2020
Co-investment VC firm supporting the mission of the Kauffman Fellows
Advisor
2019
Advisor to BrainMind, a consortium working to support advances in brain science in collaboration with leading scientists at Stanford, MIT, and Harvard.
BrainMind is an ecosystem and platform for impact-oriented company creation in brain and mind science.
Member, Board of Directors
2020 - 2024
SecureAire is a leading pathogen detection and active air filtration platform for improving indoor air quality. Their platform is a leader in reducing healthcare facility acquired infections and is expanding into commercial, residential, and industrial real estate markets.
SecureAire is a developer of an active particle control technology used to increase the overall filtration efficiency.
Member, Board of Directors
2021 - 2024
Attivare Therapeutics is using its novel biomaterial-based platform technology to vaccinate against oncology indications and infectious diseases. Our goal is to provide effective prophylactic and therapeutic treatments for a variety of unmet medical needs. Formerly known as Omnivax, Attivare spun out of Dr. Dave Mooney's lab at Harvard's Wyss Institute.
Member, Board of Directors (Observer)
2021 - 2023
Mae is a culturally competent maternal health platform that connects expectant mothers with critical resources to drive positive pregnancy outcomes.
Member Board of Directors
2020 - 2023
CloudCath is a digital health medical device company that is dedicated to remote complication monitoring for patients undergoing catheter-based treatments. Became an Observer to Board in March 2023.
Co-Founder, CEO
2015 - 2020
Healthcare investment and research marketplace. Fund business spun out as MBX Capital in July 2020.
The next-generation of healthcare and life science venture capital.
Managing Partner
2010 - 2015